Faes Farma Stock

Faes Farma Gross Margin

The Gross Margin of Faes Farma (FAE.MC) as of Aug 9, 2026 is 37.42 %. In the previous year, Gross Margin was 66.15 % — a change of -43.42% (lower).

Gross Margin

37.42 %

YoY

-43.42%

Last updated:

Gross Margin of Faes Farma is 2026 37.42 % . Gross Margin of Faes Farma was 2025 66.15 % . It decreases by -43.42% lower compared to the previous year.

For Faes Farma, the gross margin of 37.4% is down versus 63.3% a few years ago.

Access this data via the Eulerpool API

Faes Farma Stock analysis

What does Faes Farma do? The history of Faes Farma SA dates back to 1933, when the company was founded in Barcelona, Spain. The founders had a vision to develop innovative products that would contribute to improving the health and well-being of people. Over the following decades, the company grew continuously and established itself as one of the leading players in the pharmaceutical industry. The business model of Faes Farma SA is focused on the development and marketing of products for the healthcare industry. The company relies on research and development to develop innovative solutions for various therapeutic areas. Faes Farma SA distributes its products worldwide through a network of partners and distributors, with a focus on Europe and Latin America. Faes Farma SA operates in three different divisions. The first division is pharmaceuticals, where the company offers products for various areas such as respiratory diseases, allergies, pain, and inflammation. An important part of this segment is the product Bilastine, which is used for the treatment of allergies and is considered an alternative to antihistamines. The second division is animal health. Here, Faes Farma SA offers products for the treatment of pets, including preparations against fleas, ticks, and worms. One of the most well-known products in this area is the Stangest brand, which is considered the leading brand for animal health in Spain. The third division of Faes Farma SA is the business of medical devices and diagnostics. Here, the company offers a wide range of products for various medical applications, including devices for monitoring vital signs and diagnostics for infectious diseases. Overall, Faes Farma SA is a company with a diversified product portfolio that is of interest to both end consumers and healthcare professionals and pet owners. The company has continuously developed and invested in research and development in recent years to expand its product offering and provide innovative solutions for various medical needs. Faes Farma SA is a company that stands out for its commitment to the development of innovative products and its dedication to the health and well-being of humans and animals. With a strong focus on research and development and a wide distribution network, the company has solidified its position in the pharmaceutical industry and will continue to play an important role in the market. Faes Farma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Faes Farma stock

Gross Margin of Faes Farma is 37.42 % in 2026.

Gross Margin of Faes Farma changed from 66.15 % to 37.42 %, representing a -43.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Faes Farma since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Faes Farma with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Faes Farma

All Key Metrics — Faes Farma